The Summary of COVID-19 Antiviral Therapuetics flowchart illustrates the use of the antiviral treatments based on their potential to reduce progression to severe disease and hospitalization in high risk patients as of July 1, 2021:
|
Severity of Infection |
Patient Health Status |
Antiviral Treatment |
|---|
| No Illness | Health, no infection | |
|---|
| Exposed/Asymptomatic Infected | Not hospitalized, no limitations | |
|---|
| Early Symptomatic | Hospitalized, with limitations | Moncolonal Antibodies (EUA Issued) - Bamlanivimab + Etesevimab1 (Lilly)
- Casirivimab + Imdevimab (RGN)
- Sotrovimab (GSK/Vir)
|
|---|
| Hospital Admission | - Hospitalized no acute medical problems
- Hospitalized, not on oxygen
- Hospitalized on oxygen
| - Remdesivir (FDA approved)
- Tocilizumab (EUA issued)
|
|---|
| ICU Admission | - Hospitalized, high flow oxygen/non-invasive ventilation
- Hospitalized, mechanical ventilation/ECMO
| |
|---|
1.National shipment pause due to variants, as of 06/25/2021
